Literature DB >> 4008676

Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects.

N A Farid, R F Bergstrom, E A Ziege, C J Parli, L Lemberger.   

Abstract

A pharmacokinetic profile of tomoxetine, a selective norepinephrine uptake inhibitor, was developed in human volunteers following single and multiple oral administrations. Following the administration of a single 90-mg oral dose of tomoxetine to four normal volunteers, the plasma half-life was 4.3 +/- 0.5 hours. Mean plasma clearance was 0.60 +/- 0.14 L/Kg/hr, and the mean volume of distribution was 3.7 +/- 0.9 L/kg. Multiple doses of tomoxetine (20 mg bid and 40 mg bid) for seven days were administered to an additional seven subjects. The data appeared to have a bimodal distribution. The mean plasma half-life determined following the last dose was 4.6 +/- 0.5 hours in five subjects. The other two subjects, one at each dose level, demonstrated accumulation of tomoxetine occurring from the first to last dose where tomoxetine disappeared from plasma with a mean half-life of 19 hours.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4008676     DOI: 10.1002/j.1552-4604.1985.tb02842.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  10 in total

Review 1.  Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.

Authors:  Jacob T Brown; Jeffrey R Bishop; Katrin Sangkuhl; Erika L Nurmi; Daniel J Mueller; Jean C Dinh; Andrea Gaedigk; Teri E Klein; Kelly E Caudle; James T McCracken; Jose de Leon; J Steven Leeder
Journal:  Clin Pharmacol Ther       Date:  2019-04-13       Impact factor: 6.875

2.  Safety, tolerability and subject-rated effects of acute intranasal cocaine administration during atomoxetine maintenance.

Authors:  William W Stoops; John W Blackburn; David A Hudson; Lon R Hays; Craig R Rush
Journal:  Drug Alcohol Depend       Date:  2007-08-24       Impact factor: 4.492

3.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 4.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 5.  Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.

Authors:  Dene Simpson; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.

Authors:  Henry A Spiller; Hannah L Hays; Alfred Aleguas
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 7.  Clinical pharmacokinetics of atomoxetine.

Authors:  John-Michael Sauer; Barbara J Ring; Jennifer W Witcher
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

8.  Studying the association complex formation of atomoxetine and fluvoxamine with eosin Y and its application in their fluorimetric determination.

Authors:  Sayed M Derayea; Mahmoud A Omar; Ahmed A Abu-Hassan
Journal:  R Soc Open Sci       Date:  2018-03-14       Impact factor: 2.963

9.  Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: a naturalistic study.

Authors:  Katrin Ruppert; Christoph Geffert; Hans-Willi Clement; Christian Bachmann; Michael Haberhausen; Eberhard Schulz; Christian Fleischhaker; Monica Biscaldi-Schäfer
Journal:  J Neural Transm (Vienna)       Date:  2022-04-07       Impact factor: 3.850

10.  Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder.

Authors:  Fahad Aldosary; Sandhaya Norris; Philippe Tremblay; Jonathan S James; James C Ritchie; Pierre Blier
Journal:  Int J Neuropsychopharmacol       Date:  2022-04-19       Impact factor: 5.176

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.